Comments on .
作者信息
Wang Hao, Wang Jian, Wang Xiang, Zhu Yiming, Sun Yuqing, Zhang Xin, Hou Xiaorong, Zheng Kun, Liu Shaoyan, Lin Yansong
机构信息
Department of Clinical Oncology, Qingdao Municipal Hospital, Qingdao University, Qingdao 266012, China.
Department of Head and Neck Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
出版信息
Chin J Cancer Res. 2022 Oct 30;34(5):447-450. doi: 10.21147/j.issn.1000-9604.2022.05.02.
Abstract
摘要
相似文献
1
Comments on .关于……的评论
Chin J Cancer Res. 2022 Oct 30;34(5):447-450. doi: 10.21147/j.issn.1000-9604.2022.05.02.
2
Corrigendum to Comments on .关于……的评论的勘误
Chin J Cancer Res. 2022 Dec 30;34(6):644. doi: 10.21147/j.issn.1000-9604.2022.06.14.
3
Comments on .关于……的评论
Chin J Cancer Res. 2023 Oct 30;35(5):431-432. doi: 10.21147/j.issn.1000-9604.2023.05.01.
4
Comments on .关于……的评论
Chin J Cancer Res. 2022 Oct 30;34(5):453-455. doi: 10.21147/j.issn.1000-9604.2022.05.04.
5
Comments on .关于……的评论
Chin J Cancer Res. 2022 Oct 30;34(5):458-459. doi: 10.21147/j.issn.1000-9604.2022.05.06.
6
Comments on .关于……的评论
Chin J Cancer Res. 2022 Oct 30;34(5):451-452. doi: 10.21147/j.issn.1000-9604.2022.05.03.
7
Comments on .关于……的评论
Chin J Cancer Res. 2022 Oct 30;34(5):456-457. doi: 10.21147/j.issn.1000-9604.2022.05.05.
8
Comments on .关于……的评论
Chin J Cancer Res. 2022 Dec 30;34(6):637-643. doi: 10.21147/j.issn.1000-9604.2022.06.13.
9
Comments on .关于……的评论
Chin J Cancer Res. 2022 Dec 30;34(6):635-636. doi: 10.21147/j.issn.1000-9604.2022.06.12.
10
Comments on .关于……的评论
Chin J Cancer Res. 2022 Dec 30;34(6):633-634. doi: 10.21147/j.issn.1000-9604.2022.06.11.
引用本文的文献
1
An Early Thyroid Screening Model Based on Transformer and Secondary Transfer Learning for Chest and Thyroid CT Images.基于Transformer和二次迁移学习的胸部及甲状腺CT图像早期甲状腺筛查模型
Technol Cancer Res Treat. 2025 Jan-Dec;24:15330338251323168. doi: 10.1177/15330338251323168. Epub 2025 Mar 31.
2
A comprehensive analysis and comparative study of the trends in thyroid cancer burden in China and globally from 1990 to 2021, with projections for the next 15 Years.1990年至2021年中国和全球甲状腺癌负担趋势的综合分析与比较研究，并对未来15年进行预测。
Front Oncol. 2025 Feb 7;15:1505728. doi: 10.3389/fonc.2025.1505728. eCollection 2025.
3
BRAF mutation is associated with better prognoses in radioactive iodine refractory thyroid cancer patients treated with multi-kinase inhibitors: a retrospective analysis of registered clinical trials.BRAF突变与接受多激酶抑制剂治疗的放射性碘难治性甲状腺癌患者的较好预后相关：一项注册临床试验的回顾性分析
Thyroid Res. 2025 Feb 10;18(1):5. doi: 10.1186/s13044-025-00223-0.
4
Distinctive role of mutations in distant metastatic thyroid cancer.远处转移性甲状腺癌中突变的独特作用。
Chin J Cancer Res. 2024 Dec 30;36(6):700-712. doi: 10.21147/j.issn.1000-9604.2024.06.08.
本文引用的文献
1
Anlotinib in Locally Advanced or Metastatic Medullary Thyroid Carcinoma: A Randomized, Double-Blind Phase IIB Trial.安罗替尼治疗局部晚期或转移性甲状腺髓样癌的随机、双盲、IIB 期研究
Clin Cancer Res. 2021 Jul 1;27(13):3567-3575. doi: 10.1158/1078-0432.CCR-20-2950. Epub 2021 Apr 8.
2
Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in -Mutated Anaplastic Thyroid Carcinoma.达拉非尼联合曲美替尼新辅助治疗后行 - 突变型间变性甲状腺癌完全切除术。
Thyroid. 2019 Aug;29(8):1036-1043. doi: 10.1089/thy.2019.0133.
3
Active Surveillance as First-Line Management of Papillary Microcarcinoma.主动监测作为甲状腺微小乳头状癌的一线治疗方法。
Annu Rev Med. 2019 Jan 27;70:369-379. doi: 10.1146/annurev-med-051517-125510. Epub 2018 Sep 19.
4
Real-World Experience with Targeted Therapy for the Treatment of Anaplastic Thyroid Carcinoma.治疗间变性甲状腺癌的靶向治疗的真实世界经验。
Thyroid. 2018 Jan;28(1):79-87. doi: 10.1089/thy.2017.0285. Epub 2017 Dec 21.
5
Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer.达拉非尼联合曲美替尼治疗局部晚期或转移性 BRAF V600 突变型甲状腺癌患者。
J Clin Oncol. 2018 Jan 1;36(1):7-13. doi: 10.1200/JCO.2017.73.6785. Epub 2017 Oct 26.
6
Serial stimulated thyroglobulin measurements are more specific for detecting distant metastatic differentiated thyroid cancer before radioiodine therapy.在放射性碘治疗前，连续刺激甲状腺球蛋白测量对于检测远处转移性分化型甲状腺癌更具特异性。
Chin J Cancer Res. 2017 Jun;29(3):213-222. doi: 10.21147/j.issn.1000-9604.2017.03.07.
7
Prognostic value of the eighth edition AJCC TNM classification for differentiated thyroid carcinoma.第八版 AJCC TNM 分类对分化型甲状腺癌的预后价值。
Oral Oncol. 2017 Aug;71:81-86. doi: 10.1016/j.oraloncology.2017.06.004. Epub 2017 Jun 10.
8
An International Multi-Institutional Validation of Age 55 Years as a Cutoff for Risk Stratification in the AJCC/UICC Staging System for Well-Differentiated Thyroid Cancer.一项关于将55岁作为AJCC/UICC高分化甲状腺癌分期系统中风险分层临界值的国际多机构验证研究。
Thyroid. 2016 Mar;26(3):373-80. doi: 10.1089/thy.2015.0315. Epub 2016 Feb 25.
9
External-beam radiotherapy for differentiated thyroid cancer locoregional control: A statement of the American Head and Neck Society.美国头颈协会关于分化型甲状腺癌局部区域控制的外照射放疗声明
Head Neck. 2016 Apr;38(4):493-8. doi: 10.1002/hed.24357. Epub 2015 Dec 30.
10
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.2015年美国甲状腺协会成人甲状腺结节和分化型甲状腺癌管理指南：美国甲状腺协会甲状腺结节和分化型甲状腺癌指南工作组
Thyroid. 2016 Jan;26(1):1-133. doi: 10.1089/thy.2015.0020.
Zotero 插件